What is William Blair's Estimate for Korro Bio Q3 Earnings?

Key Points

• William Blair has revised upward its Q3 2025 earnings per share estimate for Korro Bio to ($2.97) from the previous forecast of ($3.03), while the consensus for the full year stands at ($9.52) per share.
• Korro Bio reported Q2 earnings of ($2.74) per share, which missed estimates of ($2.54) by ($0.20), despite exceeding revenue expectations of $0.41 million with actual revenue of $1.46 million.
• Several analysts have given Korro Bio a "buy" or "strong buy" rating, with a consensus price target of $86.83, reflecting positive sentiment despite recent target price reductions from some investment firms.

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Equities researchers at William Blair lifted their Q3 2025 EPS estimates for Korro Bio in a research note issued to investors on Tuesday, August 12th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($2.97) for the quarter, up from their previous estimate of ($3.03). The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio's Q4 2025 earnings at ($3.00) EPS, FY2025 earnings at ($11.21) EPS, Q1 2026 earnings at ($3.06) EPS, Q2 2026 earnings at ($3.09) EPS, Q3 2026 earnings at ($3.12) EPS, Q4 2026 earnings at ($3.14) EPS, FY2026 earnings at ($12.40) EPS, FY2027 earnings at ($13.19) EPS and FY2028 earnings at ($12.55) EPS.

Korro Bio (NASDAQ:KRRO - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($2.74) earnings per share for the quarter, missing analysts' consensus estimates of ($2.54) by ($0.20). The firm had revenue of $1.46 million during the quarter, compared to analysts' expectations of $0.41 million.

Several other equities analysts have also recently commented on the stock. Chardan Capital restated a "buy" rating and issued a $25.00 target price on shares of Korro Bio in a research report on Wednesday. Raymond James Financial cut their target price on Korro Bio from $153.00 to $147.00 and set a "strong-buy" rating for the company in a research note on Wednesday. Cantor Fitzgerald raised Korro Bio to a "strong-buy" rating in a report on Tuesday, April 29th. Oppenheimer dropped their price objective on Korro Bio from $155.00 to $90.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Finally, HC Wainwright reduced their price objective on Korro Bio from $100.00 to $90.00 and set a "buy" rating on the stock in a research note on Wednesday. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Korro Bio presently has a consensus rating of "Buy" and a consensus price target of $86.83.

Korro Bio Stock Up 5.0%

Shares of Korro Bio stock opened at $19.88 on Friday. Korro Bio has a 12-month low of $10.29 and a 12-month high of $98.00. The company has a market capitalization of $186.67 million, a price-to-earnings ratio of -2.04 and a beta of 2.51. The firm's 50-day moving average price is $14.20 and its two-hundred day moving average price is $18.23.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its holdings in Korro Bio by 9.0% during the 4th quarter. Bank of America Corp DE now owns 7,037 shares of the company's stock worth $268,000 after acquiring an additional 581 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Korro Bio by 4.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 18,288 shares of the company's stock valued at $318,000 after acquiring an additional 790 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Korro Bio by 32.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,392 shares of the company's stock worth $129,000 after purchasing an additional 831 shares during the period. Deutsche Bank AG lifted its holdings in shares of Korro Bio by 29.4% during the fourth quarter. Deutsche Bank AG now owns 4,110 shares of the company's stock worth $156,000 after purchasing an additional 935 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Korro Bio by 9.0% in the first quarter. Bank of New York Mellon Corp now owns 16,113 shares of the company's stock worth $281,000 after purchasing an additional 1,325 shares during the last quarter. Institutional investors own 13.18% of the company's stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.